View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: January 31, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: January 24, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland
UA UNDER ARMOUR
... (+8)

InsiderInsights.com Daily Ratings Report: January 21, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Clear Channel Outdoor Holdings, Inc.: Update to credit analysis

Our credit view of this issuer reflects its strong, steady profitability model supported by conversion to digital from static billboards, constrained by its high financial leverage.

 PRESS RELEASE

Cabaletta Bio Announces 2026 Strategic Priorities

Cabaletta Bio Announces 2026 Strategic Priorities Registrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission – including an outpatient dosing option using a single weight-based dose  IND amendment cleared to manufacture rese-cel with the automated, scalable Cellares platform based on multiple successful engineering runs; clinical manufacturing data expected in 1H26 to confirm GMP readiness, including supply chain logistics New durability data without preconditioning and higher dose initial clinical data from RESET-PV™ expected in 1H26...

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Clear Channel Outdoor Holdings, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 17 December 2025 in which we reassessed the appropriateness of the rat...

 PRESS RELEASE

Dave & Buster’s Reports Third Quarter 2025 Financial Results

Dave & Buster’s Reports Third Quarter 2025 Financial Results DALLAS, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Dave & Buster's Entertainment, Inc. (NASDAQ: PLAY) (“Dave & Buster's” or “the Company”), an owner, operator, and franchisor of entertainment and dining venues, today announced financial results for its third quarter of fiscal 2025 ended November 4, 2025. Third Quarter 2025 Financial Summary Third quarter revenue was $448.2 million, a 1.1% decrease compared to the third quarter of fiscal 2024.Third quarter comparable store sales decreased 4.0% compared to the same calendar period in fis...

 PRESS RELEASE

Dave & Buster’s Entertainment, Inc. to Report Third Quarter 2025 Finan...

Dave & Buster’s Entertainment, Inc. to Report Third Quarter 2025 Financial Results on December 9, 2025 DALLAS, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Dave & Buster's Entertainment, Inc., (NASDAQ:PLAY), ("Dave & Buster's" or "the Company"), an owner, operator, and franchisor of entertainment and dining venues, today announced that it will report financial results for its third quarter ended November 4, 2025 after the market closes on Tuesday, December 9, 2025. Management will host a conference call to discuss these results on Tuesday, December 9, 2025, at 4:00 p.m. Central Time (5:00 p.m. East...

 PRESS RELEASE

Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provide...

Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update Rese-cel data presented at multiple medical meetings demonstrated potentially transformative, drug-free clinical responses with a favorable safety profile for autoimmune patients supporting outpatient use All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who would have met key criteria for the registrational cohort met the registrational, 16-week primary endpoint Planned BLA submission for rese-cel in 2027 based on 14-patient, single-arm DM/ASyS registrational cohort initi...

 PRESS RELEASE

Cabaletta Bio to Participate in Upcoming Investor Conferences in Novem...

Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December PHILADELPHIA, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in the following upcoming investor conferences in November and December: Guggenheim’s 2nd Annual Healthcare Innovation Conference: Webcasted fireside chat at 10:30 a.m. ET on Tuesday, November 1...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

 PRESS RELEASE

Cabaletta Bio Presents Positive Clinical Data and Development Updates ...

Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025 – All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who met key registrational inclusion criteria exceeded the registrational primary endpoint, demonstrating major TIS responses with no immunomodulators – – Myositis registrational trial being initiated this quarter with a planned cohort of 14 DM/ASyS patients and a 16-week primary endpoint – moderate or major TIS while off immunomodulators and on no or low-dose steroids – consistent with FDA alignment on ...

 PRESS RELEASE

Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial...

Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant – Gavel brings highly relevant CAR T experience from Legend Biotech where he led the launch and commercialization of CARVYKTI® from 2018 until 2025 – PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced the appointment of Steve Gavel as Chief Commercial Offic...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch